secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001213900-24-041847
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Oramed CFO David Silberman resigns, effective July 12, 2024
-----------------------------------------------------------

- David Silberman stepped down as CFO, Treasurer and Secretary for personal reasons.
- His resignation is effective July 12, 2024, with a transition period until then.
- Company has initiated a search for a new CFO to replace Silberman.
- The departure is voluntary and not due to any disagreement with Oramed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024041847/0001213900-24-041847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024041847/ea0205772-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-041847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer